New hope for Alzheimer's patients

US scientists have just opened a new hope for Alzheimer's patients with a scientific work that confirms "killing" an enzyme with the scientific name Monoacylglycerol Lipase (MAGL) can help treat or prevent progress of Alzheimer's dementia.

The results of the study published on Cell Reports' network status on November 1 show that disabling MAGL, best known for its role in reducing the canabinoid compound in the brain, will help prevent production and accumulation of beta amyloid, the main cause of Alzeimer's disease.

Limiting this enzyme also reduces the swelling and degeneration of neuronal neurons, and increases the flexibility of the brain, the ability to learn and memory.

Alzheimer's disease is a symptom of neuronal degeneration disorder, which accumulates amyloid plaques, causing disruption of nerve neron microfiber, in addition to swelling of neron strings, cell division process. It happens abnormally, along with the degeneration of the cognitive functions and the brain's inability to memorize and spread the dead cells.

Around the world, there are about 36 million people suffering from Alzheimer's disease at different levels, of which more than 5.4 million people in the US alone.